title: [Present status and future prospects of antibody therapy against solid tumor].
abstract: Anti-tumor antibodies show significant anti-tumor activity against various tumor types especially by the combination with other cytotoxic drugs. Antibodies have been targeted against (1) Cell surface differentiation antigen, (2) Growth factor, (3) Growth factor receptor, (4) Signal transduction factors. By these antibodies significant increase in response rate, and prolongation of PFS/OS have been reported. Some antibodies have contributed to the establishment of new standard treatment. Patient selection has extensively been tried except for the treatment with bevacizumab. New problem appeared for the proof of principle study for immunotherapeutic antibody, ipilimumab because the mode of action of it seems to be non specific.
authors.affiliation: Secretariat of Japanese Society of Medical Oncology.
authors.forename: Nagahiro
authors.initials: N
authors.lastname: Saijo
mesh_terms: D000906:Antibodies / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity / Q000276:immunology*; D000970:Antineoplastic Agents / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000906:Antibodies; D000970:Antineoplastic Agents